Glioma cells might be sensitized to the alkylating agent temozolomide (TMZ) [21, 22], and combined therapy of IFN-β and TMZ resulted in a favorable outcome in patients with tumors with O6-methylguanine DNA methyltransferase (MGMT) promotor methylation [23]. This evidence concerns the gene IFNB1 and glioma.